The redox cycling enzymes thioredoxin, thioredoxin reductase, sulfiredoxin, peroxiredoxin, GSH peroxidase, superoxide dismutase 1, and catalase, and several GSH S-transferases, which are the enzymes mediating the elimination of ROS, are all Nrf2 targets (242)
Retatrutide is currently being investigated for its potential role in: Supporting healthy weight management Improving blood glucose regulation Enhancing insulin sensitivity Reducing appetite and food intake Increasing feelings of fullness (satiety) Increasing energy expenditure Supporting fat metabolism and fat oxidation Improving overall metabolic health Investigating obesity, type 2 diabetes, and related metabolic disorders Clinical studies have demonstrated significant weightloss and metabolic improvements, while ongoing Phase 3 trials continue to evaluate its long-term safety and effectiveness
Extended exposure above 8C accelerates degradation
the composite GI adverse event rate across any GI symptom reached approximately 80% [2]